- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00607867
LoBAG30 Diet in Patients on Metformin (LoBAG Diet)
10. december 2014 opdateret af: US Department of Veterans Affairs
Metabolic Response to a LoBAG30 Diet in Diabetic Patients on Metformin
We will determine the metabolic response to a Low Biologically Available Glucose Diet (LoBAG30) in subjects currently receiving the maximum dose of metformin as monotherapy in whom the glycohemoglobin is not at an acceptable level (>8.0%).
Our hypothesis is that introduction of a LoBAG30 diet to subjects currently treated with a full therapeutic dose of metformin will improve blood glucose control in people who have not achieved an acceptable total glycohemoglobin on metformin alone.
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Subjects will ingest a control diet (55% carbohydrate (CHO), 15% protein, 30% fat) or a LoBAG30 diet (30% CHO, 30% protein, 40% fat) in a parallel design with block randomization in pairs of two.
Subjects will return to the study center twice each week while on the diets to have blood glucose, glycohemoglobin, lactate, weight and blood pressure measured, and to have urine assayed for urea and creatinine.
At the beginning and end of the 5 week study period, the subjects will be admitted to the study center for 28 hours during which time blood will be drawn for 24 hour profiles of glucose, insulin, other hormones and several metabolites.
For those subjects randomized to the LoBAG30 arm of the study, the control diet will be given during the first 24 hour study period; the assigned diet will be given at the end of the 5 week period.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
20
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Minnesota
-
Minneapolis, Minnesota, Forenede Stater, 55417
- VA Medical Center, Minneapolis
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
50 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- People with type 2 diabetes mellitus who currently are receiving the maximal dose of metformin monotherapy (2500 mg/day).
- These subjects will have had a stable glycohemoglobin (tGHb) in an unacceptably high range (8-11%) for at least 4 months prior to beginning the study.
- Subjects with tGHB > 11% (HbA1c > 10%) will not be recruited into the study.
Exclusion Criteria:
- Hematological abnormalities
- liver disease
- kidney disease
- macroalbuminuria (>300 mg albumin/24 hours)
- untreated thyroid disease
- congestive heart failure
- angina
- life-threatening malignancies
- proliferative retinopathy
- severe diabetic neuropathy
- peripheral vascular disease
- serious psychological disorders
- a body mass index > 35
and a fasting triglyceride of >400 mg/dl.
- Subjects taking slow-release metformin will not be studied.
- Subjects taking medications other than metformin, known to affect fuel metabolism such as:
- insulin
- the sulfonylureas
- glucagon-like peptide 1 (GLP-1) analogs and metabolic inhibitors
- pramlintide
- prednisone and similar steroids
- thyroid hormone
- antipsychotic medications
- thiazide diuretics
- medroxyprogesterone
high dose aspirin, also will be excluded.
- If concentrations of serum folate, B12 or iron are low, the subject will be excluded from the study until corrected, i.e. until normal concentrations are recorded.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm 1
A LoBAG30, weight maintenance diet will be given to subjects on metformin.
All food will be provided for 5 weeks.
|
A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
|
|
Placebo komparator: Arm 2
A weight maintenance, control diet consisting of 55% carbohydrate, 15% protein, 30% fat will be given to subjects on metformin.
All food will be provided for 5 weeks.
|
A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in %Hemoglobin A1c at 5 Weeks From Baseline
Tidsramme: Baseline and 5 weeks after dietary intervention
|
Hemoglobin A1c measured before and after 5 weeks on the diet
|
Baseline and 5 weeks after dietary intervention
|
|
Change in Total Glucose Area at 5 Weeks From Baseline
Tidsramme: Baseline and 5 weeks after dietary intervention
|
The area response is measured using zero as baseline.
The area is measured before dietary intervention, and following 5 weeks of dietary intervention.
|
Baseline and 5 weeks after dietary intervention
|
|
Change in Body Weight at 5 Weeks From Baseline
Tidsramme: baseline and 5 weeks after dietary intervention
|
Subjects were to remain weight stable.
We expected less than 2 pound weight change over 5 weeks.
Weight was measured before dietary intervention, and after 5 weeks of dietary intervention.
|
baseline and 5 weeks after dietary intervention
|
|
Change in Overnight Fasting Glucose Concentration at 5 Weeks From Baseline
Tidsramme: baseline and 5 weeks after dietary intervention
|
Overnight fasting glucose concentration was measured before dietary intervention and after 5 weeks of dietary intervention.
|
baseline and 5 weeks after dietary intervention
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Microalbumin Excretion
Tidsramme: baseline and 5 weeks after dietary intervention
|
change in urinary albumin excretion was measured before dietary intervention and after 5 weeks of dietary intervention
|
baseline and 5 weeks after dietary intervention
|
|
Change in Fasting Triglycerides at 5 Weeks From Baseline
Tidsramme: baseline and 5 weeks after dietary intervention
|
Overnight fasting triglycerides concentration was measured before dietary intervention and after 5 weeks of dietary intervention
|
baseline and 5 weeks after dietary intervention
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Efterforskere
- Ledende efterforsker: Mary Gannon, PhD, Minneapolis Veterans Affairs Medical Center
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. april 2008
Primær færdiggørelse (Faktiske)
1. januar 2011
Studieafslutning (Faktiske)
1. marts 2011
Datoer for studieregistrering
Først indsendt
31. januar 2008
Først indsendt, der opfyldte QC-kriterier
5. februar 2008
Først opslået (Skøn)
6. februar 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
12. december 2014
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. december 2014
Sidst verificeret
1. december 2014
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CLIN-010-07F
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .